{"name":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","slug":"cspc-zhongqi-pharmaceutical-technology-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":13,"colorKey":"oncology","drugs":[{"name":"Glumetinib Tablets","genericName":"Glumetinib Tablets","slug":"glumetinib-tablets","indication":"Other","status":"phase_2"},{"name":"200mg","genericName":"200mg","slug":"200mg","indication":"Other","status":"marketed"},{"name":"Liposome-entrapped Mitoxantrone Hydrochloride Injection","genericName":"Liposome-entrapped Mitoxantrone Hydrochloride Injection","slug":"liposome-entrapped-mitoxantrone-hydrochloride-injection","indication":"Other","status":"phase_1"},{"name":"SYS6002","genericName":"SYS6002","slug":"sys6002","indication":"Other","status":"phase_3"},{"name":"placepo","genericName":"placepo","slug":"placepo","indication":"Other","status":"phase_3"},{"name":"400mg","genericName":"400mg","slug":"400mg","indication":"Acid Indigestion Relief","status":"marketed"},{"name":"Ammoxetine","genericName":"Ammoxetine","slug":"ammoxetine","indication":"Other","status":"phase_3"},{"name":"DP303c treatment","genericName":"DP303c treatment","slug":"dp303c-treatment","indication":"Other","status":"phase_2"},{"name":"HA121-28 tablet","genericName":"HA121-28 tablet","slug":"ha121-28-tablet","indication":"Other","status":"phase_2"},{"name":"Octreotide Acetate Microspheres for Injection injection","genericName":"Octreotide Acetate Microspheres for Injection injection","slug":"octreotide-acetate-microspheres-for-injection-injection","indication":"Other","status":"phase_1"},{"name":"Probenecid tablets","genericName":"Probenecid tablets","slug":"probenecid-tablets","indication":"Other","status":"phase_1"},{"name":"SYH9056","genericName":"SYH9056","slug":"syh9056","indication":"Other","status":"phase_3"},{"name":"SYHA1807","genericName":"SYHA1807","slug":"syha1807","indication":"Other","status":"phase_1"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"neuroscience","drugs":[{"name":"DBPR108; Placebo matching sitagliptin","genericName":"DBPR108; Placebo matching sitagliptin","slug":"dbpr108-placebo-matching-sitagliptin","indication":"Placebo control for type 2 diabetes mellitus trials","status":"phase_3"},{"name":"DP303c","genericName":"DP303c","slug":"dp303c","indication":"Type 2 diabetes","status":"phase_3"},{"name":"Placebo matching DBPR108; Sitagliptin; DBPR108","genericName":"Placebo matching DBPR108; Sitagliptin; DBPR108","slug":"placebo-matching-dbpr108-sitagliptin-dbpr108","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"semaglutide injection (HD1916)","genericName":"semaglutide injection (HD1916)","slug":"semaglutide-injection-hd1916","indication":"Treatment of type 2 diabetes","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"respiratory","drugs":[{"name":"SKLB1028","genericName":"SKLB1028","slug":"sklb1028","indication":"Solid tumors (Phase 3 development)","status":"phase_3"},{"name":"SYSA1901","genericName":"SYSA1901","slug":"sysa1901","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"},{"name":"Salvage Chemotherapy","genericName":"Salvage Chemotherapy","slug":"salvage-chemotherapy","indication":"Relapsed or refractory hematologic malignancies","status":"phase_3"},{"name":"Sandostatin ® injection","genericName":"Sandostatin ® injection","slug":"sandostatin-injection","indication":"Acromegaly (growth hormone-secreting pituitary adenoma)","status":"marketed"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"Ammoxetine Hydrochloride Enteric-coated Tablets","genericName":"Ammoxetine Hydrochloride Enteric-coated Tablets","slug":"ammoxetine-hydrochloride-enteric-coated-tablets","indication":"Attention deficit hyperactivity disorder (ADHD)","status":"phase_2"},{"name":"Duloxetine hydrochloride enteric-coated capsules","genericName":"Duloxetine hydrochloride enteric-coated capsules","slug":"duloxetine-hydrochloride-enteric-coated-capsules","indication":"Major depressive disorder","status":"phase_2"},{"name":"Hydroxocobalamin Chloride Injection","genericName":"Hydroxocobalamin Chloride Injection","slug":"hydroxocobalamin-chloride-injection","indication":"Vitamin B12 deficiency","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Amphotericin B liposomes","genericName":"Amphotericin B liposomes","slug":"amphotericin-b-liposomes","indication":"Systemic fungal infections (invasive candidiasis, aspergillosis, cryptococcosis)","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"infectious","drugs":[{"name":"Meloxicam Nanocrystal Injection","genericName":"Meloxicam Nanocrystal Injection","slug":"meloxicam-nanocrystal-injection","indication":"Acute pain management","status":"phase_3"}]}],"pipeline":[{"name":"Glumetinib Tablets","genericName":"Glumetinib Tablets","slug":"glumetinib-tablets","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"200mg","genericName":"200mg","slug":"200mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ammoxetine Hydrochloride Enteric-coated Tablets","genericName":"Ammoxetine Hydrochloride Enteric-coated Tablets","slug":"ammoxetine-hydrochloride-enteric-coated-tablets","phase":"phase_2","mechanism":"Ammoxetine hydrochloride is a norepinephrine reuptake inhibitor.","indications":["Attention deficit hyperactivity disorder (ADHD)"],"catalyst":""},{"name":"Duloxetine hydrochloride enteric-coated capsules","genericName":"Duloxetine hydrochloride enteric-coated capsules","slug":"duloxetine-hydrochloride-enteric-coated-capsules","phase":"phase_2","mechanism":"Selective serotonin and norepinephrine reuptake inhibitor","indications":["Major depressive disorder","Generalized anxiety disorder","Diabetic peripheral neuropathic pain"],"catalyst":""},{"name":"Hydroxocobalamin Chloride Injection","genericName":"Hydroxocobalamin Chloride Injection","slug":"hydroxocobalamin-chloride-injection","phase":"phase_3","mechanism":"Hydroxocobalamin chloride is a form of vitamin B12 that replaces deficient cobalamin and restores normal cellular metabolism and neurological function.","indications":["Vitamin B12 deficiency","Pernicious anemia","B12 deficiency-related neurological complications"],"catalyst":""},{"name":"Liposome-entrapped Mitoxantrone Hydrochloride Injection","genericName":"Liposome-entrapped Mitoxantrone Hydrochloride Injection","slug":"liposome-entrapped-mitoxantrone-hydrochloride-injection","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SYS6002","genericName":"SYS6002","slug":"sys6002","phase":"phase_3","mechanism":"SYS6002 is a novel therapeutic agent in clinical development by CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","indications":[],"catalyst":""},{"name":"placepo","genericName":"placepo","slug":"placepo","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"400mg","genericName":"400mg","slug":"400mg","phase":"marketed","mechanism":"Small molecule","indications":["Acid Indigestion Relief","Upset Stomach Relief"],"catalyst":""},{"name":"Ammoxetine","genericName":"Ammoxetine","slug":"ammoxetine","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Amphotericin B liposomes","genericName":"Amphotericin B liposomes","slug":"amphotericin-b-liposomes","phase":"phase_3","mechanism":"Amphotericin B disrupts fungal cell membranes by binding to ergosterol, causing leakage of cellular contents and cell death.","indications":["Systemic fungal infections (invasive candidiasis, aspergillosis, cryptococcosis)","Empirical antifungal therapy in febrile neutropenic patients"],"catalyst":""},{"name":"DBPR108; Placebo matching sitagliptin","genericName":"DBPR108; Placebo matching sitagliptin","slug":"dbpr108-placebo-matching-sitagliptin","phase":"phase_3","mechanism":"DBPR108 is a placebo matching formulation designed to match sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin levels to stimulate insulin secretion in response to glucose.","indications":["Placebo control for type 2 diabetes mellitus trials"],"catalyst":""},{"name":"DP303c","genericName":"DP303c","slug":"dp303c","phase":"phase_3","mechanism":"DP303c is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"DP303c treatment","genericName":"DP303c treatment","slug":"dp303c-treatment","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HA121-28 tablet","genericName":"HA121-28 tablet","slug":"ha121-28-tablet","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Meloxicam Nanocrystal Injection","genericName":"Meloxicam Nanocrystal Injection","slug":"meloxicam-nanocrystal-injection","phase":"phase_3","mechanism":"Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and inflammation.","indications":["Acute pain management","Rheumatoid arthritis","Osteoarthritis","Ankylosing spondylitis"],"catalyst":""},{"name":"Octreotide Acetate Microspheres for Injection injection","genericName":"Octreotide Acetate Microspheres for Injection injection","slug":"octreotide-acetate-microspheres-for-injection-injection","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Placebo matching DBPR108; Sitagliptin; DBPR108","genericName":"Placebo matching DBPR108; Sitagliptin; DBPR108","slug":"placebo-matching-dbpr108-sitagliptin-dbpr108","phase":"phase_3","mechanism":"Sitagliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels and stimulate insulin secretion in response to glucose.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Probenecid tablets","genericName":"Probenecid tablets","slug":"probenecid-tablets","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SKLB1028","genericName":"SKLB1028","slug":"sklb1028","phase":"phase_3","mechanism":"SKLB1028 is a tyrosine kinase inhibitor that targets multiple kinases involved in cancer cell proliferation and survival.","indications":["Solid tumors (Phase 3 development)"],"catalyst":""},{"name":"SYH9056","genericName":"SYH9056","slug":"syh9056","phase":"phase_3","mechanism":"SYH9056 is a small-molecule inhibitor targeting a specific kinase involved in cancer cell proliferation and survival.","indications":[],"catalyst":""},{"name":"SYHA1807","genericName":"SYHA1807","slug":"syha1807","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SYSA1901","genericName":"SYSA1901","slug":"sysa1901","phase":"phase_3","mechanism":"SYSA1901 is a monoclonal antibody targeting PD-1.","indications":["Non-small cell lung cancer, PD-L1 positive","Head and neck squamous cell carcinoma"],"catalyst":""},{"name":"Salvage Chemotherapy","genericName":"Salvage Chemotherapy","slug":"salvage-chemotherapy","phase":"phase_3","mechanism":"Salvage chemotherapy refers to a combination chemotherapy regimen administered to patients who have failed or relapsed after initial cancer treatment.","indications":["Relapsed or refractory hematologic malignancies","Chemotherapy-resistant solid tumors"],"catalyst":""},{"name":"Sandostatin ® injection","genericName":"Sandostatin ® injection","slug":"sandostatin-injection","phase":"marketed","mechanism":"Sandostatin (octreotide) is a somatostatin analog that binds to somatostatin receptors on neuroendocrine cells to inhibit the secretion of growth hormone, insulin, and other hormones.","indications":["Acromegaly (growth hormone-secreting pituitary adenoma)","Variceal bleeding in portal hypertension","Carcinoid syndrome","VIPoma (vasoactive intestinal peptide-secreting tumor)","Gastrinoma"],"catalyst":""},{"name":"semaglutide injection (HD1916)","genericName":"semaglutide injection (HD1916)","slug":"semaglutide-injection-hd1916","phase":"phase_3","mechanism":"Semaglutide injection works by mimicking the action of a natural hormone in the body called glucagon-like peptide-1 (GLP-1) to help lower blood sugar levels.","indications":["Treatment of type 2 diabetes","Weight management in adults with obesity"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-04-07","type":"trial","source":"The Manila Times","summary":"Severe Asthma Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight | DelveInsight - The Manila Times","headline":"Severe Asthma Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNR19zTmNNVGZBdFRDbUxrM1loU0xGSDNYNUJuS0ZZT3JYZHZpalRweFNTbkl1WU9VQVBjRHg3ZWk2VWYyb0dYYmloTWVLeFVKNUhmVng4dGRWR0hBb3FoSEZQQ3l5MkpmaWpLaDFpTWlhMmVBNi1yTG9id1BpbGtOZUJJbEZaRlFsNE16T0xSeTRjUHkwN3p0Sjl1dzVVM1lzTzBrcHNOUFRKZDdKNzhPSjdoVQ?oc=5","date":"2025-06-13","type":"deal","source":"AstraZeneca","summary":"AstraZeneca enters strategic collaboration with CSPC Pharmaceuticals focused on AI-enabled research - AstraZeneca","headline":"AstraZeneca enters strategic collaboration with CSPC Pharmaceuticals focused on AI-enabled research","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAJBVV95cUxOVE85QlhZaUcxdWVBeHZGaHZxcWJ6N21naFV1cTFROExZRS1nRjRadnQwZWpfMlVJLTl0aW94VExXUkxDSDFfZEY5V01WLVVDSjJTS1lvbUJaWnBtQ2FDQXphODFXeEtUdjJRVHllUEp3WlpYQlluQWpuWlE3TWZmYnNJT0tSazY2OVprRS1BTV9VQzdQQnQ5d1RRVXpaSnJ4RjJRaXhoNkYzbURUMEFWeHZJZmhsRGdRUng4djFZUTNXVWd4b19fUDJxNnhkeTNWQ09kaVZIVk1zUTNNQm5DYTV6YzFnNFFhTnVrTEhjMmFwQzZXdjNTMHhSRTdsRkxhaVZhcXlZbm5YRU9uSHljc2VIQmNBWGpMSjlnb09WcTgtU0x2c0FUV0Y3aUc?oc=5","date":"2025-05-08","type":"pipeline","source":"GlobeNewswire","summary":"High- and Low-Grade Serous Ovarian Cancer Market is - GlobeNewswire","headline":"High- and Low-Grade Serous Ovarian Cancer Market is","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxPTXAzTGhpb3Q5d053WkRsSk5nZ0R0TnpJV3JjV3JuXzRZT3F3cUxLME9lem8xSzVEX3lvaHQ4cjVzQWV4bnJjMHBYUnQ1cXNZTVJIMkVqVEw1NjJDSUhwbE43MHd6c3ViRzQwZGp1c1p2MEtxUU1ZdXNVLWtkRmpjT3ItT0Q5Wk50akdSb0wzOURfZDdSZkRzOGlDaUJYaWFFd09YcEtuS0dVQU1TeUFLWnlCa1dXMjhGa3M4Z0dR?oc=5","date":"2024-12-12","type":"pipeline","source":"Business Wire","summary":"BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor - Business Wire","headline":"BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogJBVV95cUxQUlBEN2JQMkVlejVsUDE0d0pQcXhDTHBHdE1nMmhzTVNERFBfTDkzWW83Yi1ZZEpBbHowUjA1S0VpNnJ2NXZnUHRJY09NUDVxZnp2WFNxc1I2Q0x3dTFldXhFNm5JUDR5MlA4a0tDeTUxYm5WYTZMVzZUczJHYjBHbDFFaDRiTDZTSlJNRzFnbHBjNUYwNkR3ejJGa3AweDlpeVdhdk5ucGJmSHctSTdHS3g5N2lMYU1fMDB3TlYtUlBScG4zYUI4bk5LQjVlaGt3blZ5OWRfdkVCY2NFcWYtZ1UxVGxrZWJtZExQSGxFYUN4c1ZSQWhaZkxhT1M1RXRudlNuRXNlMXQ3MzFPMkZTeFRvS3VVaHprWlpsazd1akZOUQ?oc=5","date":"2024-11-06","type":"trial","source":"PR Newswire","summary":"Severe Asthma Clinical Trial Pipeline Appears Robust With 40+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - PR Newswire","headline":"Severe Asthma Clinical Trial Pipeline Appears Robust With 40+ Key Pharma Companies Actively Working in the Therapeutics ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwJBVV95cUxNbDVNY2Vtekhac0k0RU5Rc0hGN3FTVFA2UTRaMlRvbnduYW54TEtEUFpmdjIzYWUxQ1k1Rmt4R3JtVEtPTkFQMWRhTmxtOEctdGJMN0RCSlJ2dWxsWWRkN0xucC1ETkxZSnhEX0JEeGZVTXpTMjZSeDJwbWphbGRQa3lNTEFkTG5XOUZDZ1ZSa0JXWFlUbGFhRDZ0M29QSlIxQUg1Rk8wMXlUUEFEWG5CQndyS0tDQVp2T2tmM0lzeTZRSEtIbk1DVzY3ZWVpX0RZcWJ6MWtSS0FJd21JTTNwVXcxeHpBSXJlVHl3MmIxMUtlQWVLaVlfTVhvWUdobkRiVDFTM0pkWTFYSHo4RjN3TU1VYUV5dk1XZjRya3ptcUwwREpUamVveE9QYU4zSUxSU3djOWZNTQ?oc=5","date":"2024-10-01","type":"trial","source":"GlobeNewswire","summary":"Breast Cancer Clinical Trial Pipeline Appears Robust With - GlobeNewswire","headline":"Breast Cancer Clinical Trial Pipeline Appears Robust With","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowJBVV95cUxQNU56YXp3SXVHRGlSLWxQTm1BdHdmN3dCeEdIakdOSHUxWEJ6ZGl6SlJfeWNUTnJDdW5SRjZCUHM0WVljTXFmMmhkWkhLS3dVY1lhWENJV2dvVzFiM1pvRlJCVE9rcUxvQlJwV3VpRzhSLUQycjI3ZzJ5RGI0Ulc0MzFJMGxYeDl4ZUxkUXBpVmxqa1dqakhKY0hNcExNX0FkQUpuZEVCd2sycjBXOTNPcnBXbVlyTkpubmNaX0NUYmFkTUVlUkk1OUZxeWVkYWtOaXJNNmpYdEFqUUJXQjJaUmQ0czhVcG43ZV82OE9CbHA5am1odlMzQ0N5WGZFX1Q4VkxvbjZKTFN0aE8zRE92V1NYNXlBRjBYY0k2M2VIU2oyVXM?oc=5","date":"2023-01-30","type":"pipeline","source":"PR Newswire","summary":"Acute Myeloid Leukemia Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 200+ Companies Working in the Domain - PR Newswire","headline":"Acute Myeloid Leukemia Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 200+ Companie","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTFBrNFZjZHU4QmhlVmhybU9iQlA0UldaR3c0Qk1QSnJFaXMyTTkxMWlEMDZWYlRGdmpxTElFYW5BZVE2Yl9WQmhwdU5UMmVuUnFIbmZTUnNxV2ZaaGdZMFhoVHVSZHltakZm?oc=5","date":"2023-01-23","type":"pipeline","source":"Straits Research","summary":"FLT3 Inhibitors Market Size, Top Share, Report to 2033 - Straits Research","headline":"FLT3 Inhibitors Market Size, Top Share, Report to 2033","sentiment":"neutral"}],"patents":[],"drugCount":26,"phaseCounts":{"phase_2":5,"marketed":3,"phase_3":14,"phase_1":4},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}